Drug intelligence / Profile preview

SAR446523

Development stage: Phase 1
Lead developer: Sanofi
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

SAR446523 is an investigational anti-GPRC5D monoclonal antibody being developed for the treatment of relapsed or refractory multiple myeloma. It is designed as an ADCC-enhanced antibody, meaning it is engineered to improve antibody-dependent cellular cytotoxicity against cancer cells expressing GPRC5D. The drug is administered subcutaneously and is currently in Phase 1 clinical trials to evaluate its safety, antitumor activity, pharmacokinetics, and pharmacodynamics in patients who have received at least three prior lines of therapy for multiple myeloma[1][2][3][4][5][7].

Targets

GPRC5D

Beyond the preview

Go deeper on SAR446523.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAR446523.

Explore the full profile